

Abstract

An agent for intra-airway administration comprising a compound having a PDE-IV inhibitory activity or the pharmaceutically acceptable salt thereof as an active ingredient which shows its concentration in lung tissues 350-times or more higher than its concentration in plasma when administered into the airway is provided. An agent for intra-airway administration, wherein the compound having a PDE-IV inhibitory activity is, for example, a benzofuran derivative or a 1,3-benzodioxole derivative is provided.